|
|
|
Volumn 5, Issue 4, 2003, Pages 437-447
|
|
Technology evaluation: TNFerade, GenVec
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLCYSTEINE;
ADENOVIRUS VECTOR;
CISPLATIN;
FLUOROURACIL;
FREE RADICAL;
GAMMA INTERFERON;
HYDROGEN PEROXIDE;
MELPHALAN;
RADIOSENSITIZING AGENT;
REACTIVE OXYGEN METABOLITE;
SCAVENGER;
TNFERADE;
TRANSCRIPTION FACTOR;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
ANGINA PECTORIS;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BLOOD CLOTTING DISORDER;
CANCER;
CANCER RADIOTHERAPY;
CAPILLARY LEAK SYNDROME;
CHILL;
CLINICAL STUDY;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG INDICATION;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TISSUE LEVEL;
FEVER;
GENE CONTROL;
GENE TECHNOLOGY;
HEART ATRIUM FIBRILLATION;
HUMAN;
HYPOTENSION;
INJECTION PAIN;
LEUKOPENIA;
METABOLIC ACIDOSIS;
MULTIPLE ORGAN FAILURE;
NAUSEA;
NONHUMAN;
PATENT;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PROMOTER REGION;
RADIOSENSITIVITY;
RESPIRATORY DISTRESS;
SHOCK;
STRUCTURE ACTIVITY RELATION;
TISSUE INJURY;
TOXICITY TESTING;
VIRAL GENE DELIVERY SYSTEM;
VIRAL GENE THERAPY;
VIRUS REPLICATION;
ANIMALS;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
GENE THERAPY;
HUMANS;
NEOPLASMS;
TECHNOLOGY, PHARMACEUTICAL;
TUMOR NECROSIS FACTOR-ALPHA;
ADENOVIRIDAE;
|
|
EID: 0042326321
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
